Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral Birch
Stallergenes Greer, a biopharmaceutical company specialising in the diagnosis and treatment of respiratory allergies, announced today the initiation of a Phase III clinical study (YOBI, YOung patients
Source: finanznachrichten.de